• Promethera Biosciences

  Participated · Series B · Mar 2012

  Promethera develops cell-based therapies and complementary biologics to reduce the need for liver transplantation, with lead programs derived from its patented HepaStem platform. Its lead product candidate, HepaStem, consists of expanded liver stem cells manufactured under cGMP and is being evaluated in a phase 2a trial in ACLF with safety and efficacy results presented at EASL 2019. The company is preparing to initiate a late-stage clinical trial in NASH, planned to start in Europe and expand to the US and Asia. Promethera also advances H2Stem and antibody programs such as the anti-TNF-R1 antibody Atrosimab to diversify its pipeline. The company operates internationally with facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland). The organization is scaling manufacturing and advancing preclinical work while progressing multiple clinical programs. Promethera Biosciences is a global innovator in cell-based medicines focused on severe liver diseases. Its lead clinical program is derived from the company’s patented HepaStem cell technology platform, which the company says has immune-modulatory and anti-fibrotic properties. In addition to cell-based therapies, Promethera develops antibody technologies to complement and diversify its therapeutic options. The company operates R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, North Carolina, USA. It recently acquired Baliopharm AG, adding an antibody candidate that specifically binds TNF-R1 to its pipeline. Promethera plans to use new funding to accelerate and broaden clinical development in indications with significant unmet need, including acute-on-chronic liver failure (ACLF), NASH and fibrosis. Promethera Biosciences is a clinical-stage biopharmaceutical company focused on cell therapy and regenerative medicine for inborn and acquired liver diseases. It develops products using allogeneic progenitor cells, stem cells and mature hepatocytes harvested from non-transplantable healthy human livers (HHALPC, HHLivC) and has three cell products: HepaStem, H2Stem, and Heparesc. The pipeline targets both orphan indications (urea cycle disorders, α1‑antitrypsin deficiency, hemophilia) and larger indications such as acute-on-chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatitis (NASH). Promethera plans to expand its development focus to these larger indications and accelerate clinical development toward the clinic. Headquartered in Mont-Saint-Guibert, Belgium, Promethera was founded in 2009 as a spin-off of Université catholique de Louvain and maintains a U.S. operation with a GMP manufacturing facility in Durham, North Carolina. The company raised EUR 10 million in a Series C-extension to fund these initiatives and support expansion into Asian markets. Promethera Biosciences develops Promethera® HepaStem, a cell-based therapy for in-born errors of metabolism and acquired liver diseases, and Promethera® H2Screen and H3Screen, non-therapeutic in vitro products based on a patented liver progenitor cell type. The company was founded in 2009 as a spin-off of the Université Catholique de Louvain (UCL) and is led by CEO Eric Halioua. It is clinical-stage and intends to use recent funding to advance the clinical development of HepaStem and a collaborative program with EMD-Millipore. The platform is based on cells isolated from healthy adult human livers. Promethera has 44 employees. Promethera Biosciences develops and commercializes allogeneic progenitor-cell products to treat liver diseases and offers liver cell models for the pharmaceutical industry. Its lead products include Promethera® HepaStem, a cell therapy for severe liver diseases in children and adults, and Promethera® HepaScreen, a cell model that mimics human liver metabolism and detoxification for drug testing. The company was founded in 2009 as a spin-off of the Université Catholique de Louvain and is led by CEO Eric Halioua. Promethera is based in Mont-Saint-Guibert, Belgium and currently employs 40 people. In March 2012 it raised €23.6m in a Series B composed of a €17m capital increase and a €6.6m loan from the Walloon Region. New strategic and financial backers in the round include Boehringer Ingelheim, Shire, Mitsui Global Investment, ATMI and SambrInvest, joining earlier Series A investors.

No current team members are available.